Bupleurum in Treatment of Depression Disorder: A Comprehensive Review.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI, c2004-

The incidence of depression has been steadily rising in recent years, making it one of the most prevalent mental illnesses. As the pursuit of novel antidepressant drugs captivates the pharmaceutical field, the therapeutic efficacy of Traditional Chinese Medicine (TCM) has been widely explored. Chaihu ( Bupleurum ) has been traditionally used for liver conditions such as hepatitis, liver inflammation, liver fibrosis, and liver cancer. It is believed to have hepatoprotective effects, promoting liver cell regeneration and protecting against liver damage. In addition, Bupleurum has also been used as a Jie Yu (depression-relieving) medicine in China, Japan, Republic of Korea, and other Asian countries for centuries. This review article aims to summarize the research conducted on the antidepressant properties and mechanisms of Bupleurum , as well as discuss the potential of TCM formulas containing Bupleurum . This review highlights various antidepressant ingredients isolated from Bupleurum , including saikosaponin A, saikosaponin D, rutin, puerarin, and quercetin, each with distinct mechanisms of action. Additionally, Chinese herb prescriptions and extracts containing Bupleurum , such as Chaihu Shugansan, Xiaoyaosan, and Sinisan, are also included due to their demonstrated antidepressant effects. This review reveals that these Bupleurum compounds exhibit antidepressant effects through the regulation of neurotransmitter mechanisms (such as 5-HT and DA), the NMDA (N-methyl-D-aspartate) system, brain-derived neurotrophic factor (BDNF), and other intracellular signaling pathways. Collectively, this comprehensive review provides insights into the multiple applications of Bupleurum in the treatment of depression and highlights its potential as an alternative or complementary approach to traditional therapies. However, it is essential to consider the potential adverse effects and clinical restrictions of Bupleurum despite its promising potential. Further research is needed to elucidate its specific mechanisms of action and evaluate its effectiveness in human subjects.

J Psychiatr Res. 2016 Nov;82:109-18. (PMID: 27491067)
J Ethnopharmacol. 2014 Dec 02;158 Pt A:1-10. (PMID: 25448502)
Neuropsychiatr Dis Treat. 2021 Apr 06;17:1001-1019. (PMID: 33854318)
Eur Neuropsychopharmacol. 2019 Jul;29(7):825-834. (PMID: 31227264)
Pharmacopsychiatry. 2005 Mar;38(2):69-77. (PMID: 15744630)
Psychopharmacology (Berl). 2017 Nov;234(22):3385-3394. (PMID: 28875366)
Front Pharmacol. 2019 Jan 09;9:1537. (PMID: 30687098)
Front Immunol. 2022 Oct 24;13:1006434. (PMID: 36353622)
Front Pharmacol. 2021 Apr 12;12:586788. (PMID: 33912031)
Curr Neuropharmacol. 2015;13(4):514-23. (PMID: 26412071)
Front Pharmacol. 2018 Sep 28;9:1098. (PMID: 30323763)
Expert Opin Drug Saf. 2003 May;2(3):249-62. (PMID: 12904104)
Cell Prolif. 2019 Nov;52(6):e12696. (PMID: 31599060)
J Ethnopharmacol. 2024 Jan 10;318(Pt B):117016. (PMID: 37567427)
Nutr Neurosci. 2023 Oct;26(10):997-1010. (PMID: 36039913)
Front Pharmacol. 2022 Apr 08;13:865376. (PMID: 35462940)
J Cell Mol Med. 2020 Jan;24(1):174-188. (PMID: 31762213)
J Affect Disord. 2021 Jul 1;290:353-363. (PMID: 34049088)
Basic Clin Pharmacol Toxicol. 2008 Oct;103(4):305-13. (PMID: 18834353)
Phytother Res. 2023 Mar;37(3):809-819. (PMID: 36447385)
Antioxidants (Basel). 2022 Oct 27;11(11):. (PMID: 36358493)
J Clin Psychiatry. 2014 May;75(5):e441-9. (PMID: 24922496)
J Ethnopharmacol. 2023 Apr 24;306:116129. (PMID: 36638855)
Epidemiol Psychiatr Sci. 2019 Apr 05;29:e30. (PMID: 30947759)
Behav Brain Res. 2021 May 21;406:113245. (PMID: 33745981)
Am J Psychiatry. 2016 Aug 1;173(8):816-26. (PMID: 27056608)
Behav Brain Res. 2021 Apr 9;403:113138. (PMID: 33493495)
Oxid Med Cell Longev. 2021 Oct 18;2021:7716201. (PMID: 34707778)
Inflammation. 2016 Aug;39(4):1453-61. (PMID: 27251379)
Front Chem. 2021 Sep 30;9:747987. (PMID: 34660539)
Am J Psychiatry. 2014 Apr;171(4):404-15. (PMID: 24362450)
Neurosciences (Riyadh). 2020 Jan;25(1):55-60. (PMID: 31982896)
Front Pharmacol. 2022 Oct 11;13:1010520. (PMID: 36304143)
Mol Psychiatry. 2022 Jan;27(1):58-72. (PMID: 34257409)
Neural Regen Res. 2018 May;13(5):837-845. (PMID: 29863014)
Free Radic Biol Med. 2023 Apr;199:141-153. (PMID: 36841364)
Biol Pharm Bull. 2022 Jul 1;45(7):863-871. (PMID: 35491088)
Expert Rev Neurother. 2013 Aug;13(8):883-6. (PMID: 23965162)
Mol Psychiatry. 2016 Jun;21(6):786-96. (PMID: 27067014)
Am J Psychiatry. 2020 May 1;177(5):381-390. (PMID: 32354265)
Mol Psychiatry. 2014 Jul;19(7):791-800. (PMID: 23958957)
BMC Complement Altern Med. 2016 Jul 07;16:192. (PMID: 27389194)
Biomed Res Int. 2017;2017:7597596. (PMID: 28593176)
Brain Behav Immun. 2019 Nov;82:106-121. (PMID: 31394209)
Life Sci. 1998;63(13):1147-56. (PMID: 9763210)
Neuropsychiatr Dis Treat. 2020 Dec 08;16:3023-3033. (PMID: 33324063)
J Ethnopharmacol. 2020 Jun 28;256:112806. (PMID: 32234596)
Psychol Med. 2023 Jan;53(2):351-361. (PMID: 33952359)
Brain Res Bull. 2020 Apr;157:69-76. (PMID: 31926302)
Mol Psychiatry. 2020 Mar;25(3):530-543. (PMID: 31801966)
Basic Clin Pharmacol Toxicol. 2021 May;128(5):661-668. (PMID: 33369126)
Front Pharmacol. 2020 Jan 17;10:1544. (PMID: 32009956)
Mol Biol Rep. 2022 Sep;49(9):8801-8813. (PMID: 36002654)
J Ethnopharmacol. 2013 Dec 12;150(3):805-17. (PMID: 24184193)
Psychiatry Clin Neurosci. 2018 Jan;72(1):3-12. (PMID: 28926161)
Neurosci Lett. 2017 Aug 24;656:65-71. (PMID: 28732760)
Nature. 1978 Aug 24;274(5673):801-2. (PMID: 210393)
Front Pharmacol. 2022 Oct 19;13:1040591. (PMID: 36339629)
Nat Rev Neurosci. 2015 Apr;16(4):189-200. (PMID: 25790864)
J Ethnopharmacol. 2009 Jul 30;124(3):481-7. (PMID: 19467314)
J Ethnopharmacol. 2024 Jan 30;319(Pt 3):117289. (PMID: 37844745)
Expert Rev Neurother. 2014 May;14(5):539-51. (PMID: 24738823)
Ann Intern Med. 2011 Dec 6;155(11):772-85. (PMID: 22147715)
Br J Pharmacol. 2022 Aug;179(16):4078-4091. (PMID: 35362097)
Pharmacol Res. 2021 Sep;171:105740. (PMID: 34246781)
Drug Des Devel Ther. 2022 Aug 23;16:2783-2801. (PMID: 36039087)
Biomed Pharmacother. 2019 Apr;112:108621. (PMID: 30798141)
Neuropharmacology. 2019 Sep 1;155:150-161. (PMID: 31145906)
Hum Exp Toxicol. 2006 Aug;25(8):481-94. (PMID: 16937920)
Am J Psychiatry. 2014 Dec 1;171(12):1328-34. (PMID: 25158141)
Biosci Rep. 2019 Jan 11;39(1):. (PMID: 30473537)
J Ethnopharmacol. 2023 Apr 6;305:116110. (PMID: 36581162)
J Altern Complement Med. 2020 Jan;26(1):8-24. (PMID: 31328996)
Biomed Res Int. 2022 Nov 9;2022:1024693. (PMID: 36408279)
Alcohol. 2023 Feb;106:22-29. (PMID: 36306976)
Front Pharmacol. 2021 Feb 16;12:625074. (PMID: 33776766)
Cell. 2022 Jan 6;185(1):62-76. (PMID: 34963057)
Brain Behav Immun. 2020 Aug;88:471-481. (PMID: 32283293)
Nat Neurosci. 2015 Oct;18(10):1386-93. (PMID: 26404713)
Int Immunopharmacol. 2020 Mar;80:106181. (PMID: 31926446)
Biomed Pharmacother. 2020 Apr;124:109787. (PMID: 31958763)
Pharmacol Res. 2024 Mar;201:107090. (PMID: 38309381)
Psychoneuroendocrinology. 2008 Jul;33(6):693-710. (PMID: 18602762)
Int J Neuropsychopharmacol. 2014 Oct 31;18(4):. (PMID: 25522416)
Acta Diabetol. 2023 Jun;60(6):805-815. (PMID: 36920548)
Front Pharmacol. 2021 Dec 15;12:767333. (PMID: 34975477)
Front Pharmacol. 2022 Apr 06;13:773537. (PMID: 35462897)
Aliment Pharmacol Ther. 2010 Jul;32(2):289-95. (PMID: 20456311)
Neuropsychiatr Dis Treat. 2020 Apr 20;16:1043-1050. (PMID: 32368066)
Rev Endocr Metab Disord. 2021 Jun;22(2):179-204. (PMID: 33770352)
Biol Psychiatry. 1974 Oct;9(2):147-59. (PMID: 4154114)
Molecules. 2022 Oct 27;27(21):. (PMID: 36364141)
Carbohydr Polym. 2012 Jun 20;89(2):448-52. (PMID: 24750742)
Eur J Pharmacol. 2008 Jun 10;587(1-3):163-8. (PMID: 18457827)
Chin Med. 2022 May 24;17(1):60. (PMID: 35610650)
PLoS One. 2011 Jan 12;6(1):e16064. (PMID: 21264326)
Phytomedicine. 2021 Nov;92:153736. (PMID: 34560520)
Semin Cardiothorac Vasc Anesth. 2004 Dec;8(4):317-34. (PMID: 15583792)
J Steroid Biochem Mol Biol. 2021 Feb;206:105795. (PMID: 33246157)
Neurosci Lett. 2018 Jan 1;662:283-289. (PMID: 28958685)
J Ethnopharmacol. 2023 Jun 28;310:116375. (PMID: 36934787)
Neuropharmacology. 2023 Jan 1;222:109305. (PMID: 36354092)
J Pharm Biomed Anal. 2023 Feb 20;225:115202. (PMID: 36586383)
Brain Res. 2021 Dec 1;1772:147661. (PMID: 34529966)
Lancet Psychiatry. 2018 Jan;5(1):65-78. (PMID: 28757132)

Grant No. 2022YFE0201000 National Key R&D Program of China; Grants No. 82174002 and 82204652 National Natural Science Foundation of China; Grant No. 202206010109 Guangzhou Science and Technology Planning Project; Grant No. 202201011429 Guangzhou Science and Technology Planning Project; Grant No. 2021A1515110571 GuangDong Basic and Applied Basic Research Foundation; Grant No. 2021M691258 China Postdoctoral Science Foundation

Keywords: Bupleurum; Chinese traditional formula; active ingredients; antidepressant; depression

Date Created: 20240427 Latest Revision: 20240429

20240429

PMC11054835

10.3390/ph17040512

38675471